Key Points
- David Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, reducing his holding by about 8.46% to 551,881 shares valued near $16.8M.
- Broad insider selling continued across the company — director Ian T. Clark sold 264,800 shares (~$7.87M) and Naseem Zojwalla disposed of a combined ~269,509 shares this week, indicating notable insider pressure.
- Market and analyst context: OLMA shares are trading down (about 1.8%), the company has negative EPS/P‑E metrics, but analysts maintain a "Moderate Buy" consensus with an average price target of ~$40.50.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider David Myles sold 51,000 shares of the firm's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.46, for a total value of $1,553,460.00. Following the completion of the transaction, the insider owned 551,881 shares in the company, valued at approximately $16,810,295.26. This trade represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Olema Pharmaceuticals Trading Down 1.8%
Shares of OLMA stock opened at $27.67 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -14.80 and a beta of 1.87. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $36.26. The firm has a fifty day moving average price of $18.58 and a 200-day moving average price of $10.56.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). As a group, equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.
More Olema Pharmaceuticals News
Here are the key news stories impacting Olema Pharmaceuticals this week:
- Negative Sentiment: Naseem Zojwalla sold 99,509 shares on Dec. 23 at an average $27.66 for ~$2.75M; holding afterward fell to 4,488 shares (a ~95.7% reduction). SEC Form 4 - Zojwalla sale 12/23/2025
- Negative Sentiment: Naseem Zojwalla sold 70,000 shares on Dec. 19 at an average $28.20 for ~$1.97M; his reported direct holding dropped ~40% after that trade. SEC Form 4 - Zojwalla sale 12/19/2025
- Negative Sentiment: Naseem Zojwalla sold 100,000 shares on Dec. 22 at an average $28.04 for ~$2.80M; his combined transactions over the week materially reduced his stake. SEC Form 4 - Zojwalla sale 12/22/2025
- Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, trimming his position by ~8.5%. SEC Form 4 - Myles sale 12/19/2025
- Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at an average $29.73 for ~$7.87M — a very large director-level disposal that can amplify market concern. SEC Form 4 - Clark sale 12/19/2025
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on OLMA shares. Zacks Research raised Olema Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, September 9th. The Goldman Sachs Group increased their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a "buy" rating in a research note on Thursday, December 11th. Citigroup lifted their target price on Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, December 12th. JPMorgan Chase & Co. increased their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 18th. Finally, UBS Group restated a "buy" rating on shares of Olema Pharmaceuticals in a report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $40.50.
Check Out Our Latest Research Report on Olema Pharmaceuticals
Institutional Trading of Olema Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its holdings in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after buying an additional 2,168 shares during the period. Farther Finance Advisors LLC raised its position in Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock valued at $29,000 after acquiring an additional 5,866 shares in the last quarter. FNY Investment Advisers LLC boosted its position in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after purchasing an additional 5,000 shares in the last quarter. Quarry LP purchased a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $45,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Olema Pharmaceuticals during the 1st quarter worth approximately $52,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
